alexa Ciprofloxacin For The Treatment Of Non-resolving Pneumonia In A Tertiary Care Pediatric Hospital
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

9th Annual European Pharma Congress
June 26-28, 2017 Madrid, Spain

Mohammed K El-Habil
Al-Rantisy Specialized Pediatric Hospital, Gaza
Posters & Accepted Abstracts: Pharmaceut Reg Affairs
DOI: 10.4172/2167-7689-C1-025
Purpose: Data regarding the use of ciprofloxacin in children with no resolving pneumonia are scarce. The present study aims to evaluate the effect of ciprofloxacin therapy in pediatric patients with non-resolving pneumonia. Methods: Over the past year, all pediatric patients with non-resolving pneumonia who received ciprofloxacin treatment in the pulmonary unit of Al-Rantisy Specialized Pediatric Hospital in Gaza, Palestine, were included in this retrospective study. Ciprofloxacin was given for all patients in a dose of 20 mg/kg/day divided into two doses. Patient demographic data, clinical symptoms recorded, sputum culture findings and ciprofloxacin therapeutic outcome were gathered. Data were analyzed using computer software SPSS version 11. Results: The study included 57 patients with non-resolving pneumonia, 36 males and 21 females with mean age of 3.4 years, ranged from 2 months to 8 years. Fever (73.7%) and cough (89.5%) were the most common symptoms. Positive culture was obtained in 42 (73.6%) patients while 15 (26.4%) showed negative results. The most common organism isolated in the positive cultures was Pseudomonas aeruginosa 26 (62.0%). Among the study sample, 23 (40.4%) patients received ciprofloxacin as empirical therapy and 34 (59.6%) received this drug depending on culture sensitivity results. There was a significant decrease in body temperature levels (P<0.001) at day 1, 2 and 3 of ciprofloxacin treatment. Overall, ciprofloxacin was effective in the treatment of 53 (93.0%) patients of the present study. Only 4 (7%) cases showed resistant to this therapy. The mean length of hospital stay was 7.5 days. No side effects were reported during the course of this study. Conclusion: Data of the present study suggest that ciprofloxacin is effective and safe, including as initial monotherapy, for the treatment of pediatric patients with no resolving pneumonia.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version